Login / Signup

Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis.

Akaninyene Asuquo OtuFelix BongominRohit BazazChris HarrisDavid W DenningChris Kosmidis
Published in: Mycoses (2018)
Micafungin may be safely administered via an OPAT service. Micafungin therapy was associated with an improvement or stability in QoL scores in at least 50% of the patients across the four domains.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • healthcare
  • mental health
  • peritoneal dialysis
  • staphylococcus aureus
  • patient reported outcomes
  • mesenchymal stem cells
  • cell therapy